STAT

SEPTEMBER 14, 2024

BARCELONA, Spain — Patients with advanced cancers often develop a secondary condition that causes them to shed weight, making it even harder to tolerate their cancer treatments. Called cachexia, it’s an under-recognized syndrome that researchers are still trying to tease out, and one that’s attracting more interest from drugmakers.

321

321

pharmaphorum

SEPTEMBER 14, 2024

ESMO 2024 began on Friday 13th September. Prof Andres Cervantes discussed how building trust has been a several generation development, following five decades of effort in the oncological space.

115

115

STAT

SEPTEMBER 14, 2024

BARCELONA, Spain — A widely used immunotherapy approach helped stave off disease progression in patients with a type of anal tumor, researchers reported Saturday, potentially setting up the drug for approval in a cancer that’s largely caused by human papillomavirus.  The Phase 3 trial tested the PD-1 targeting antibody retifanlimab in combination with chemotherapy versus chemotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the anal canal.

Chemotherapy 298

Chemotherapy Drug Development 298

BioPharma Dive

SEPTEMBER 14, 2024

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

70

70

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

Pharmacy Times

SEPTEMBER 14, 2024

An ESMO 2024 presentation explores the growing role of the gut microbiome in immunotherapy response, emerging diagnostic tools such as PCR chips, and innovative therapies such as fecal microbiota transplantation and microbiome-preserving strategies to improve patient outcomes.

46

46

Pharmacy Times

SEPTEMBER 14, 2024

The gut and intratumoral microbiota influence cancer development, progression, and treatment responses, highlighting the potential for treatment strategies that leverage these microbial interactions to enhance cancer therapies.

26

26